Immediate Impact
40 standout
Citing Papers
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
2024 Standout
Targeted protein degradation: advances in drug discovery and clinical practice
2024 Standout
Works of Mohamed Gamil being referenced
Simeprevir plus sofosbuvir for eight or 12 weeks in treatment‐naïve and treatment‐experienced hepatitis C virus genotype 4 patients with or without cirrhosis
2016
Optimizing treatment for HCV genotype 4: PEG‐IFN alfa 2a vs. PEG‐IFN alfa 2b; the debate continues
2013
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Mohamed Gamil | 144 | 125 | 59 | 19 | 226 | |
| Gianpaolo Vidili | 50 | 83 | 84 | 19 | 255 | |
| Abeer Awad | 45 | 102 | 85 | 20 | 222 | |
| Apurva Shah | 102 | 132 | 53 | 25 | 238 | |
| Thanh Tran | 49 | 67 | 37 | 17 | 179 | |
| A. Gimson | 60 | 72 | 91 | 15 | 282 | |
| Anne Wernet | 104 | 32 | 130 | 13 | 259 | |
| Manlio Prosperi | 134 | 97 | 121 | 18 | 249 | |
| Kaushal Madan | 95 | 188 | 86 | 17 | 281 | |
| Juan Canabal | 117 | 62 | 138 | 21 | 236 | |
| John K. Maring | 91 | 63 | 165 | 15 | 266 |
All Works
Loading papers...